PTC Therapeutics, Inc. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2020-12-31 was $0.00.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2020-09-30 was $0.00.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2020-06-30 was $42.87M.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2018-12-31 was -$1.00K.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2020 was $42.87M.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2018 was $155.86M, a 107.29% increase from fiscal 2017.
- PTC Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2017 was $75.19M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $42.87M 10-K · filed 2023-02-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | |
| 2020-06-30 | $42.87M 10-Q · filed 2021-07-29 | |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $155.86M 10-K · filed 2021-02-25 |
| 2018-09-30 | $155.86M 10-Q · filed 2019-10-30 | |
| 2017-12-31 | $75.19M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |